Military Medical Research and Development
CFDA 12.420 · Federal Grants & Funding
Total Funding
$9.67B
Awards
5K
Recipients
719
States
49
Last Updated
Apr 1, 2026
Yearly Funding Trend
| Fiscal Year | Obligations | Awards | YoY Change |
|---|---|---|---|
| 2024 | $7.19B | 3K | |
| 2025 | $2.48B | 2K | -65.5% |
Award Type Mix
| Type | Obligations | Awards |
|---|---|---|
| $0 | 0 | |
| $0 | 0 |
Top 50 Awards under CFDA 12.420
Largest individual obligations for Military Medical Research and Development.
| Award | Recipient | Awarding Agency | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_W81XWH1120174_097 US MILITARY HIV RESEARCH PROGRAM. THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE FUNDS IN THE AMOUNT OF $10,530.06 DUE TO THE RECEIPT OF A REFUND CHECK, CLEARING DOC: 15009832… | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Maryland | Department of Defense Defense Health Agency | BETHESDA, MD-08 | 2024 | $2,265,729,366 |
ASST_NON_W81XWH1820040_097 ADDRESSING THE THREATS OF HIV AND EMERGING INFECTIOUS DISEASE TO THE MILITARY AND GLOBAL COMMUNITY THROUGH INNOVATIVE RESEARCH. 1. INCORPORATES A STOP WORK ORDER TERM IN ACCORDANC… | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Maryland | Department of Defense Defense Health Agency | BETHESDA, MD-08 | 2024 | $800,631,761 |
ASST_NON_W81XWH1220006_097 MEDICAL TROPICAL RESEARCH LABORATORY PROGRAM PRINCIPAL | AFRIMS THAI COMPONENT | Department of Defense Defense Health Agency | — | 2024 | $74,531,880 |
ASST_NON_W81XWH1320041_097 INFECTIOUS DISEASE, VACCINE, CLINICAL TRIAL AND ENTOMOLOGY AWARD | KENYA MEDICAL RESEARCH INSTITUTE | Department of Defense Defense Health Agency | — | 2024 | $67,205,571 |
ASST_NON_W81XWH2120043_097 COMPREHENSIVE HIV/AIDS PREVENTION, CARE AND TREATMENT IN CENTRAL UGANDA. INCORPORATE A STOP WORK ORDER TERM IN ACCORDANCE W ITH THE PRESIDENTS EXECUTIVE ORDER REEVALUATING AND REA… | MAKERERE UNIVERSITY WALTER REED PROGRAM LIMITED | Department of Defense Defense Health Agency | — | 2024 | $53,718,832 |
ASST_NON_HT94252320059_097 IMPROVING TREATMENT OF TRAUMATIC WOUNDS F ROM POINT-OF-INJURY TO HOSPITAL | SOLVENTUM US LLC Minnesota | Department of Defense Defense Health Agency | SAINT PAUL, MN-04 | 2024 | $34,191,124 |
ASST_NON_W81XWH1920067_097 LONG-TERM IMPACT OF MILITARY-RELEVANT BRAIN INJURY CONSORTIUM (LIMBIC) AWARD CHANGE IN KEY PERSONNEL | VIRGINIA COMMONWEALTH UNIVERSITY Virginia | Department of Defense Defense Health Agency | RICHMOND, VA-04 | 2024 | $24,907,742 |
ASST_NON_HT94252520003_097 CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER Texas | Department of Defense Defense Health Agency | HOUSTON, TX-09 | 2025 | $19,100,256 |
ASST_NON_W81XWH1320052_097 GENITOURINARY/LOWER ABDOMEN RECONSTRUCTION DE-OBLIGATE FUNDS TO CLOSE AWARD 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH… | WAKE FOREST UNIVERSITY HEALTH SCIENCES North Carolina | Department of Defense Defense Health Agency | WINSTON SALEM, NC-10 | 2025 | $19,002,641 |
ASST_NON_HT94252520006_097 USING COMBINATORIAL THERAPIES WITH DENDRITIC CELL THERAPIES TO IMPROVE SURVIVAL AND PREVENT RECURRENCE OF BREAST CANCER LEPTOMENINGEAL DISEASE (LMD) | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. Florida | Department of Defense Defense Health Agency | TAMPA, FL-14 | 2025 | $18,696,738 |
ASST_NON_W81XWH1620003_097 MILITARY SUICIDE RESEARCH CONSORTIUM: EXTENSION TO NEW OPPORTUNITIES AND CHALLENGES DE-OBLIGATE FUNDS FROM REFUND CHECK TO CLOSE AWARD | FLORIDA STATE UNIVERSITY Florida | Department of Defense Defense Health Agency | TALLAHASSEE, FL-02 | 2024 | $16,366,880 |
ASST_NON_W81XWH1420134_097 COMPUTATIONAL BIOLOGY INITIATIVE F OR MILITARY MEDICINE DE-OBLIGATE FUNDS TO CLOSE AWARD | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Maryland | Department of Defense Defense Health Agency | BETHESDA, MD-08 | 2025 | $15,678,530 |
ASST_NON_W81XWH2230001_097 NEUROFIBROMATOSIS RESEARCH PROGRAM CLINICAL TRIAL CONSORTIUM AWARD PROVIDES INCREMENTAL FUNDING | UNIVERSITY OF ALABAMA AT BIRMINGHAM Alabama | Department of Defense Defense Health Agency | BIRMINGHAM, AL-07 | 2024 | $15,543,767 |
ASST_NON_W81XWH1420004_097 CRANIOMAXILLOFACIAL REGENERATION FOCUS AREA DE-OBLIGATE FUNDS TO CLOSE AWARD AND 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESE… | WAKE FOREST UNIVERSITY HEALTH SCIENCES North Carolina | Department of Defense Defense Health Agency | WINSTON SALEM, NC-10 | 2025 | $15,167,764 |
ASST_NON_W81XWH1720030_097 WOMEN'S ISCHEMIA TRIAL TO REDUCE EVENTS IN NON-OBSTRUCTIVE CAD (WARRIOR) EXTEND THE PERIOD OF PERFORMANCE | UNIVERSITY OF FLORIDA Florida | Department of Defense Defense Health Agency | GAINESVILLE, FL-03 | 2024 | $14,915,728 |
ASST_NON_W81XWH1420003_097 EXTREMITY REGENERATION FOCUS AREA DE-OBLIGATE FUNDS TO CLOSE AWARD 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH ACQUISITI… | WAKE FOREST UNIVERSITY HEALTH SCIENCES North Carolina | Department of Defense Defense Health Agency | WINSTON SALEM, NC-10 | 2025 | $14,431,744 |
ASST_NON_W81XWH2010272_097 A PHASE 2B MULTICENTER STUDY OF THE COMPARATIVE EFFICACY AND SAFETY OF TRANSENDOCARDIAL INJECTION OF MSC IN PATIENTS WITH NONISCHEMIC DILATED CARDIOMYOPATHY EXTEND THE PERIOD OF P… | UNIVERSITY OF MIAMI Florida | Department of Defense Defense Health Agency | MIAMI, FL-27 | 2024 | $13,675,128 |
ASST_NON_W81XWH2120044_097 PROJECT MARCH: MULTISITE ADVANCEMENT OF RESEARCH ON CHRONIC POSTTRAUMATIC HEADACHE REMOVE THE FEDERAL INTERAGENCY TRAUMATIC BRAIN INJURY RESEARCH INFORMATICS SYSTEM (FITBIR) TERM… | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO Texas | Department of Defense Defense Health Agency | SAN ANTONIO, TX-20 | 2024 | $13,572,388 |
ASST_NON_W81XWH1320053_097 COMPOSITE TISSUE ALLOTRANSPLANTATION AND IMMUNOMODULATION DE-OBLIGATE FUNDS TO CLOSE AWARD 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY ME… | WAKE FOREST UNIVERSITY HEALTH SCIENCES North Carolina | Department of Defense Defense Health Agency | WINSTON SALEM, NC-10 | 2025 | $13,510,105 |
ASST_NON_HT94252311015_097 CENTER FOR MILITARY PERFORMANCE AND RESILIENCE. 1. EXERCISE THE OPTION ON CLIN 0003 AND PROVIDE FULL FUNDING TO CLIN 0003 IN THE AMOUNT OF $4,650,500. THE TOTAL FUNDED AND AWARDED… | PENNINGTON BIOMEDICAL RESEARCH CENTER Louisiana | Department of Defense Defense Health Agency | BATON ROUGE, LA-06 | 2024 | $13,146,160 |
ASST_NON_W81XWH2010432_097 COOLING TO HELP INJURED LUNGS (CHILL) PHASE 2B RANDOMIZED CONTROL TRIAL OF THERAPEUTIC HYPOTHERMIA IN PATIENTS WITH ARDS EXTEND THE PERIOD OF PERFORMANCE AND ADD THREE ENROLLMENTS… | UNIVERSITY OF MARYLAND, BALTIMORE Maryland | Department of Defense Defense Health Agency | BALTIMORE, MD-07 | 2024 | $12,877,617 |
ASST_NON_W81XWH1520079_097 COMPARATIVE ADJUVANT STUDY FOR DNA/PROTEIN PRIME/BOOST HIV-1 VACCINE. 1. EXTENDENTS THE POP BY 12 MONTHS: THE FINAL TECHNICAL REPORT WILL BECOME AN ANNUAL TECHNICAL REPORT DUE 30… | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Maryland | Department of Defense Defense Health Agency | BETHESDA, MD-08 | 2024 | $11,897,338 |
ASST_NON_HT94252510222_097 A RANDOMIZED CONTROLLED MULTISITE TRIAL EVALUATING SAINT FOR POSTPARTUM DEPRESSION | MAGNUS MEDICAL INC California | Department of Defense Defense Health Agency | BURLINGAME, CA-15 | 2025 | $11,619,193 |
ASST_NON_W81XWH2110739_097 POLYCYSTIC KIDNEY DISEASE: A DISORDER OF GLOMERULOTUBULAR SYNCHRONIZATION EXTEND THE PERIOD OF PERFORMANCE | YALE UNIV Connecticut | Department of Defense Defense Health Agency | NEW HAVEN, CT-03 | 2025 | $11,577,868 |
ASST_NON_W81XWH2110563_097 SAFETY AND IMMUNOGENICITY OF H3N2 M2SR MONOVALENT INFLUENZA VACCINE ADMINISTERED WITH INACTIVATED FLU VACCINE IN OLDER SUBJECTS EXTEND THE PERIOD OF PERFORMANCE REMOVE PAYMENT RES… | FLUGEN INC Wisconsin | Department of Defense Defense Health Agency | MADISON, WI-02 | 2024 | $11,439,843 |
ASST_NON_W81XWH2210272_097 THE REGENERATIVE MEDICINE FOR EB AND RELATED DISEASES AT STANFORD | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Defense Defense Health Agency | STANFORD, CA-16 | 2025 | $11,354,522 |
ASST_NON_W81XWH1820044_097 ALCOHOL AND SUBSTANCE ABUSE DISORDERS RESEARCH PROGRAM CONSORTIUM AWARD, EXTEND THE PERIOD OF PERFORMANCE | RESEARCH TRIANGLE INSTITUTE North Carolina | Department of Defense Defense Health Agency | RESEARCH TRIANGLE PARK, NC-04 | 2024 | $11,127,189 |
ASST_NON_W81XWH1610385_097 CORRECTING THE ANTI-HER-2 CD4 TH1 RESPONSE IN BREAST CANCER THERAPY TO PREVENT RECURRENCE THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE $13,151.29, AS A RESULT OF THE COMPLETI… | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. Florida | Department of Defense Defense Health Agency | TAMPA, FL-15 | 2024 | $10,850,836 |
ASST_NON_HT94252410543_097 CELL-MATRIX INTERACTIONS PROMOTING IDIOPATHIC PULMONARY FIBROSIS | UNIVERSITY OF WISCONSIN SYSTEM Wisconsin | Department of Defense Defense Health Agency | MADISON, WI-02 | 2024 | $10,824,505 |
ASST_NON_HT94252510466_097 IMPROVEMENT OF TAFENOQUINE RADICAL CURE BY COMBINATION WITH SJ733, A NOVEL ATP4 INHIBITOR, FOR TREATMENT OF MALARIA | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE Kentucky | Department of Defense Defense Health Agency | LEXINGTON, KY-06 | 2025 | $10,606,583 |
ASST_NON_W81XWH2220081_097 PHARMACOTHERAPIES FOR ALCOHOL AND SUBSTANCE USE DISORDER RESEARCH PROGRAM CONSORTIUM THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE YEAR 3, OPTION 2 FUNDING TO CLIN 0003 (FULLY F… | RESEARCH TRIANGLE INSTITUTE North Carolina | Department of Defense Defense Health Agency | RESEARCH TRIANGLE PARK, NC-04 | 2024 | $10,575,000 |
ASST_NON_HT94252411055_097 A SINGLE-SHOT THERAPY WILL ACCELERATE THE ELIMINATION OF BREAST CANCER | DUKE UNIVERSITY North Carolina | Department of Defense Defense Health Agency | DURHAM, NC-04 | 2024 | $10,478,390 |
ASST_NON_HT94252320045_097 ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES (AFRIMS) INFECTIOUS DISEASE RESEARCH. 1. APPLIES INCREMENTAL FUNDING IN THE AMOUNT OF $1,144,982 VIA PR 0012241004. 2. UPDATES… | AFRIMS THAI COMPONENT | Department of Defense Defense Health Agency | — | 2024 | $10,226,017 |
ASST_NON_W81XWH2010270_097 DEVELOPMENT AND ADVANCEMENT OF BROAD-SPECTRUM RESPIRATORY ANTIVIRALS DE-OBLIGATE FUNDS TO CLOSE AWARD | SCRIPPS RESEARCH INSTITUTE California | Department of Defense Defense Health Agency | LA JOLLA, CA-50 | 2024 | $10,202,542 |
ASST_NON_W81XWH1520069_097 TEAM APPROACH TO THE PREVENTION AND TREATMENT OF POST-TRAUMATIC EPILEPSY (TAPTE) DE-OBLIGATE FUNDS TO CLOSE AWARD 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDA… | CITIZENS UNITED FOR RSEARCH IN EPILEPSY Illinois | Department of Defense Defense Health Agency | CHICAGO, IL-07 | 2025 | $10,079,499 |
ASST_NON_W81XWH1710532_097 MULTICENTER RANDOMIZED TRIAL OF EVEROLIMUS IN PEDIATRIC HEART TRANSPLANTATION EXTEND THE PERIOD OF PERFORMANCE | CHILDREN'S HOSPITAL CORPORATION, THE Massachusetts | Department of Defense Defense Health Agency | BOSTON, MA-07 | 2024 | $10,075,335 |
ASST_NON_W81XWH1810590_097 NOVEL STRATEGIES TO COMBAT POST-TRAUMATIC OSTEOARTHRITIS (PTOA) EXTEND THE PERIOD OF PERFORMANCE | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Defense Defense Health Agency | STANFORD, CA-16 | 2024 | $10,000,000 |
ASST_NON_W81XWH1910534_097 A MULTIDISCIPLINARY TRANSLATIONAL APPROACH TO INVESTIGATE THE MECHANISMS, PREDICTORS, AND PREVENTION OF PERSISTENT POST-TRAUMATIC HEADACHE EXTEND THE PERIOD OF PERFORMANCE | MAYO CLINIC ARIZONA Arizona | Department of Defense Defense Health Agency | SCOTTSDALE, AZ-01 | 2024 | $9,999,820 |
ASST_NON_W81XWH1710429_097 PATHOGENESIS OF VASCULAR MALFORMATIONS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: FROM DISEASE MECHANISM TO NEW THERAPIES EXTEND THE PERIOD OF PERFORMANCE 1. PER SECTION 711 OF THE… | DIGNITY HEALTH California | Department of Defense Defense Health Agency | SAN FRANCISCO, CA-11 | 2024 | $9,933,291 |
ASST_NON_HT94252510204_097 PILOT RANDOMIZED CONTROLLED TRIAL OF THE ISENS SYSTEM FOR SENSORIMOTOR RESTORATION AFTER LIMB LOSS | CASE WESTERN RESERVE UNIVERSITY Ohio | Department of Defense Defense Health Agency | CLEVELAND, OH-11 | 2025 | $9,870,517 |
ASST_NON_W81XWH1720024_097 COMPUTATIONAL INITIATIVE FOR PERFORMANCE MONITORING | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Maryland | Department of Defense Defense Health Agency | BETHESDA, MD-08 | 2025 | $9,831,900 |
ASST_NON_W81XWH2110565_097 ADVANCEMENT OF CRISPR-BASED ADIPOSE TISSUE THERAPIES FOR TYPE 2 DIABETES TO NONHUMAN PRIMATES EXTEND THE PERIOD OF PERFORMANCE 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZA… | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL Massachusetts | Department of Defense Defense Health Agency | WORCESTER, MA-02 | 2025 | $9,706,177 |
ASST_NON_W81XWH1720037_097 NEUROFIBROMATOSIS CLINICAL CONSORTIUM AWARD EXTEND THE PERIOD OF PERFORMANCE | UNIVERSITY OF ALABAMA AT BIRMINGHAM Alabama | Department of Defense Defense Health Agency | BIRMINGHAM, AL-07 | 2024 | $9,462,000 |
ASST_NON_W81XWH2010807_097 TREATMENT STRATEGIES FOR MITOCHONDRIAL DISEASE EXTEND THE PERIOD OF PERFORMANCE AND REMOVE THE PAYMENT RESTRICTION CLAUSE OHRO HUMAN USE APPROVAL 1. PER SECTION 711 OF THE NATIONA… | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK New York | Department of Defense Defense Health Agency | NEW YORK, NY-13 | 2025 | $9,413,709 |
ASST_NON_W81XWH2210301_097 TITRE: TRIAL OF INDICATION-BASED TRANSFUSION OF RED BLOOD CELLS IN ECMO REMOVES THE SPECIAL TERM AND CONDITION PAYMENTS FOR AWARDS THAT REQUIRE HUMAN USE APPROVAL 1. PER SECTION 7… | CHILDREN'S HOSPITAL CORPORATION, THE Massachusetts | Department of Defense Defense Health Agency | BOSTON, MA-07 | 2024 | $8,927,797 |
ASST_NON_W81XWH1810667_097 A PHASE 2 STUDY OF INHALED CO FOR THE TREATMENT OF ARDS THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE INTO THE AWARD TERMS AND CONDITIONS A STOP WORK ORDER, AT THE DIRECTION… | WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY New York | Department of Defense Defense Health Agency | NEW YORK, NY-12 | 2024 | $8,914,310 |
ASST_NON_W81XWH1810791_097 CLINICAL TRIAL OF ETANERCEPT (TNF-ALPHA BLOCKER) FOR TREATMENT OF BLAST-INDUCED TINNITUS EXTEND THE PERIOD OF PERFORMANCE | WAYNE STATE UNIVERSITY Michigan | Department of Defense Defense Health Agency | DETROIT, MI-13 | 2024 | $8,651,782 |
ASST_NON_W81XWH1820062_097 THE GULF WAR ILLNESS CLINICAL TRIALS AND INTERVENTIONS CONSORTIUM (GWICTIC) REMOVES SPECIAL REQUIREMENTS FOR ANNUAL/FINAL TECHNICAL REPORTS 1. PER SECTION 711 OF THE NATIONAL DEFE… | NOVA SOUTHEASTERN UNIVERSITY, INC Florida | Department of Defense Defense Health Agency | FORT LAUDERDALE, FL-25 | 2024 | $8,500,000 |
ASST_NON_W81XWH1510292_097 FOLATE RECEPTOR ALPHA VACCINES FOR PREVENTING PROGRESSION OF TNBC FOLLOWING FIRST-LINE CONVENTIONAL THERAPY | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) Florida | Department of Defense Defense Health Agency | JACKSONVILLE, FL-05 | 2024 | $8,497,233 |
ASST_NON_HT94252510293_097 BEMPEDOIC ACID THERAPY FOR POLYCYSTIC KIDNEY DISEASE (BEAT-PKD) RANDOMIZED CLINICAL TRIAL | UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE Vermont | Department of Defense Defense Health Agency | BURLINGTON, VT-00 | 2025 | $8,491,997 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Spending by State
| State | Funding | Awards |
|---|---|---|
| Maryland | $3.50B | 293 |
| California | $728.7M | 528 |
| Texas | $554.8M | 471 |
| New York | $540.8M | 443 |
| Massachusetts | $498.3M | 403 |
| Pennsylvania | $324.6M | 286 |
| Florida | $317.7M | 203 |
| North Carolina | $312.8M | 195 |
| Ohio | $234.1M | 199 |
| Washington | $203.9M | 168 |
| Illinois | $188.6M | 154 |
| Minnesota | $170.4M | 106 |
| Virginia | $149.2M | 97 |
| Michigan | $128.9M | 121 |
| Colorado | $126.5M | 97 |
| Wisconsin | $105.5M | 76 |
| Tennessee | $93.9M | 84 |
| Utah | $85.2M | 52 |
| Missouri | $84.7M | 75 |
| Connecticut | $83.0M | 70 |
| Alabama | $81.4M | 55 |
| Georgia | $73.1M | 75 |
| Arizona | $69.3M | 43 |
| Kentucky | $63.3M | 43 |
| New Jersey | $57.2M | 48 |
| Indiana | $56.5M | 64 |
| Oregon | $56.1M | 46 |
| Arkansas | $33.8M | 23 |
| District of Columbia | $32.9M | 33 |
| Louisiana | $32.5M | 23 |
| Nebraska | $23.9M | 33 |
| Iowa | $22.4M | 24 |
| New Mexico | $22.4M | 13 |
| Kansas | $21.9M | 21 |
| New Hampshire | $20.6M | 16 |
| Vermont | $20.2M | 9 |
| Oklahoma | $18.8M | 22 |
| South Carolina | $18.7M | 25 |
| Rhode Island | $13.9M | 14 |
| Delaware | $10.2M | 7 |
| Maine | $9.6M | 9 |
| Puerto Rico | $8.5M | 5 |
| Mississippi | $3.8M | 6 |
| Montana | $1.5M | 1 |
| Nevada | $1.5M | 4 |
| South Dakota | $1.2M | 3 |
| Hawaii | $567K | 1 |
| West Virginia | $558K | 1 |
| North Dakota | $417K | 1 |
Top Recipients
Agencies Administering This Program
Department of Defense$9.67B
Source: USAspending.gov · All Programs